Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Symptoms and General Pathology

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Syndrome

Lymphoma

Leukemia

Leukemia, Myeloid

Preleukemia

Myelodysplastic Syndromes

Leukemia, Lymphoid

Leukemia, Lymphocytic, Chronic, B-Cell

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Neoplasms by Histologic Type

Hematologic Diseases

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Bone Marrow Diseases

Lymphatic Diseases

Leukemia, B-Cell

Chronic Disease

Disease Attributes

Myeloproliferative Disorders

Lymphosarcoma

Chronic Graft Versus Host Disease

Chronic Lymphocytic Leukemia

Acute Graft Versus Host Disease

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Chronic Myeloproliferative Disorders

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Cyclophosphamide

Fludarabine

Fludarabine phosphate

Imatinib Mesylate

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Patients with Chronic Myelogenous Leukemia (CML) who have failed or refused Gleevec(TM) therapy and will receive Donor Lymphocyte Infusion.

Patients with non-CML or CML who have failed Donor Lymphocyte Infusion (DLI) and will receive induction chemotherapy plus DLI.

donor cells infused over 2 hrs at cell dose of 0.5 dx 10\^8 CD3+T-cells/kg

Donor Lymphocyte Infusion

Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV

Induction Chemotherapy

Jeffrey Miller, MD

The purpose of this study is to test the hypothesis that a pre-infusion preparative regimen of cyclophosphamide and fludarabine will improve the effectiveness of DLI in patients with blood cancers.

When cancer relapses after donor bone marrow transplantation, regular dose chemotherapy offers little hope of prolonged survival. However, there is evidence that lymphocytes can attack cancer cells. There is considerable evidence that this immune attack on cancer cells is associated with graft-versus-host disease. Although graft-versus-host disease can cause problems, this immune reaction may, in part, be the way that bone marrow transplantation cures cancer. In this study we hope that infusion of immune cells from the subject's bone marrow donor plus a chemotherapy regimen of cyclophosphamide and fludarabine will activate the subject's immune system to attack their cancer.

Post Transplant Donor Lymphocyte Infusion

Use of Cyclophosphamide/Fludarabine to Promote in Vivo Expansion of Donor Lymphocyte Infusions (DLI) to Enhance Efficacy After Allogeneic Transplant

The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.

Overall survival will be defined as time from date of enrollment to date of death or censored at the date of last documented contact for patients still alive.

The number of patients alive one year after treatment without any signs or symptoms of the cancer being treated or any other type of cancer. In a clinical trial, measuring the disease-free survival is one way to see how well a new treatment works.

In complete remission, all signs and symptoms of cancer that can be detected with modern technology have disappeared, although cancer still may be in the body.

Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.

Aplastic anemia is a disorder in which the bone marrow greatly decreases or stops production of blood cells.

In aplastic anemia, the basic structure of the marrow becomes abnormal, and those cells responsible for generating blood cells (hematopoietic cells) are greatly decreased in number or absent. These hematopoietic cells are replaced by large quantities of fat.

Masonic Cancer Center, University of Minnesota

Cyclophosphamide 60mg/kg IV over 2 hours Fludarabine 25 mg/m2 IV over 30 minutes DLI Cell Dose 1.0 x 10\^8 CD3+ T-cells/kg

DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg

Cyclophosphamide 60mg/kg IV over 2 hours Fludarabine 25 mg/m2 DLI Cell Dose 0.5 x 10\^8 CD3+ T-cells/kg

DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg

Total

Age, Categorical

Sex: Female, Male

Due to this study starting about 15 years ago, this data is not accessible at this point. The race data WAS collected, but it was collected on all of the patients, but was not split by arm so there is not way at this point to separate the demographic data by arm. If it's possible to report the race data on the trial as a whole instead of by arm, please let me know! As of now, I have entered this in as accurate as possible given the data available to me.

Race (NIH/OMB)

Dr. Jeffrey Miller

Number of Patients Alive

Number of Patients Alive Without Disease

Number of Participants With Complete Remission

Number of Patients With Acute Graft-Versus-Host Disease

Number of Patients With Bone Marrow Aplasia

Patients who have failed or refused Gleevec (TM) therapy and will receive Donor Lymphocyte Infusion.

Donor Lymphocyte Infusion: donor cells infused over 2 hrs at cell dose of 0.5 dx 10\^8 CD3+T-cells/kg

Chronic Myelogenous Leukemia (CML)

Patients with non-CML or CML who have failed DLI and will receive Induction Chemotherapy + DLI.

Induction Chemotherapy + DLI: Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV Donor Lymphocyte Infusion (DLI)

Non-CML or CML Failing Donor Lymphocyte Infusion

Overall Study

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Diseases and Abnormalities at or Before Birth

Hematologic Neoplasms

Leukemia, Myeloid, Acute

Hodgkin Disease

Wilms Tumor

Lymphoma, Non-Hodgkin

Acute Disease

Precancerous Conditions

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Chronic Myeloid Leukemia

Hodgkin Lymphoma

Wilms' Tumor

Antipyretics

Analgesics

Anti-Allergic Agents

Antiemetics

Central Nervous System Depressants

Gastrointestinal Agents

Dermatologic Agents

Acetaminophen

Molgramostim

Sargramostim

Vaccines

Immunomodulating Agents

Diphenhydramine

Promethazine

Interleukin-4

Keyhole-limpet hemocyanin

Adjuvants, Vaccine

Analgesics, Non-Narcotic

Hypnotics and Sedatives

Anesthetics

Anesthetics, Local

Histamine H1 Antagonists

Histamine

Histamine phosphate

Histamine Antagonists

Neurotransmitter Agents

Adjuvants, Immunologic

Related and unrelated donors undergo lymphapheresis to prepare cellular vaccines and to donate lymphocytes for infusion.

Participants receive donor lymphocytes and vaccines prepared from donors.

WT1 Peptide-Pulsed Dendritic Cells

Lymphocytes from donors (related or unrelated) collected via lymphapheresis.

Donor Lymphocytes

water-soluble protein; this study will use GMCSF (granulocyte macrophage colony stimulating factor)/IL-4 generated monocyte derived dendritic cells

IL-4

Neoantigen known to induce helper responses; will be used concurrently as a vaccine adjuvant and control antigen.

WT1 Peptides

Purified lipopolysaccharide prepared from E.Coli 0:113

Endotoxin

Terry J Fry, M.D.

Background:

* Most patients with acute lymphoblastic leukemia (ALL) and many patients with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and non-Hodgkin's lymphoma (NHL) have a protein called Wilm's Tumor 1 (WT1) in their cancer cells. This protein is thought to be able to influence the growth of these cancers.
* A vaccine made with the WT1 protein may boost the immune system to help fight these cancers in patients whose cancer cells contain the protein.

Objectives:

* To determine the safety, effectiveness and side effects of giving the WT1 vaccine and donor white blood cells to patients with AML, ALL, CML or NHL who have previously received standard treatment and undergone stem cell transplantation.
* To determine the immune response to the WT1 vaccine and donor white blood cells in these patients and to determine if the response is related to the amount of WT1 protein in the patient's cancer cells.

Eligibility:

* Patients between 1 and 75 years of age with the blood antigen human leukocyte antigen (HLA-A2) and the WT1 cancer protein who have persistent or recurrent blood cancers after stem cell transplantation.
* The prior stem cell transplant donor must be willing to provide additional cells, which will be used to prepare the cellular vaccines and for donor lymphocyte (white blood cell) infusions.

Design:

* Patients are given the WT1 vaccine every 2 weeks for 6 weeks (weeks 0, 2, 4, 6, 8, 10). Each vaccination consists of two injections in the upper arm or thigh.
* On weeks 0, 4 and 8, patients also receive white blood cells from a donor to enhance the immune response. The cells are also given as a 15- to 30-minute infusion through a vein about 1 hour after the vaccine injection. Donor infusions are given only to patients with mild or no graft-vs-host disease resulting from their prior stem cell transplantation.
* Periodic physical examinations, blood and urine tests, scans to evaluate disease and other tests as needed are done for 12 months after enrollment in the study.

Background:

* Efforts to incorporate anti-tumor immunotherapy at stages of minimal residual disease (MRD) burden are limited by profound host immune depletion associated with standard anti-cancer therapies.
* Allogeneic blood and marrow stem cell transplantation (SCT) can be curative for a number of hematologic malignancies. Part of the success of this approach is an allogeneic immunologic reaction that has been demonstrated to play a role in the eradication of residual malignant disease after transplant in certain cancers (the so called graft-versus-leukemia, GVL, or graft-versus-tumor, GVT, effect). Nonetheless, relapse remains the primary cause of treatment failure after allogeneic SCT.
* The Wilm's tumor 1 (WT1) gene product is a tumor-associated antigen that represents a potential target for immunotherapy in a wide array of cancers. WT1 is expressed in most cases of acute leukemia and in many cases of chronic myelogenous leukemia and myelodysplastic syndromes. Importantly, WT1 has limited expression in normal tissues beyond embryogenesis. This trial represents an attempt to incorporate antigen-specific immunotherapy in the setting of allogeneic adoptive cell transfer.

Objectives:

* To determine the safety, toxicity, and feasibility of donor-derived dendritic cell vaccination and donor lymphocyte infusion (DLI) after allogeneic SCT.
* To determine the frequency and severity of graft-vs.-host disease (GVHD) in patients treated with peptide-loaded donor-derived dendritic cell vaccination and donor lymphocyte infusion (DLI).
* To evaluate whether immunologic responses to WT1-specific peptides can be generated by peptide-loaded donor-derived dendritic cell vaccination and DLI after allogeneic SCT.
* To evaluate whether clinical responses to WT1-specific peptides can be generated by peptide-loaded donor-derived dendritic cell vaccination and DLI after allogeneic SCT.
* To evaluate whether immunologic and/or clinical responses may be associated with the degree of WT1 expression by malignant cells or pre-existing donor anti-WT1 immunity.

Eligibility:

* HLA-A2 plus patients may be enrolled on this trial if they have relapsed or residual disease following allogeneic SCT for a WT1 expressing hematologic malignancy.
* Donors from the previous SCT, related or unrelated, must be 5- or 6- antigen genotypic HLA-matched (single HLA-A or B locus mismatch allowed) and HLAA2 plus.

Design:

* This is a pilot study, the primary aim of which is to assess safety and feasibility of this novel vaccine strategy aimed to enhance the GVL effect after allogeneic SCT.
* Donor-derived dendritic cells prepared from peripheral blood monocytes will be loaded with a combination of three WT1-derived peptides. These peptides are each comprised of one WT1-derived oligomeric epitope known to bind to HLA-A2 and an 11-mer protein transduction epitope known to enhance peptide loading and antigen presentation.
* Patients will receive donor-derived dendritic cell vaccines every 14 days for 6 doses. Donor leukocyte infusions (DLI) will also be administered with the vaccine.
* Study endpoints will include toxicity, feasibility, antigen-specific immunity, and disease response.
* This is an exploratory pilot trial. Up to 12 patients will be treated.
* Stopping rules will take effect if excessive toxicity (e.g., GVHD) or inability to generate vaccines are observed.

Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood

A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies

Here is the number of participants with adverse events. For details of the adverse events, see the adverse event module.

Acute Graft versus Host Disease (GVHD) was graded by the modified Glucksberg scale. 0 = no GVHD normal, 4 = severe GVHD.

Immune response was monitored by use of interferon gamma Enzyme-Linked Immunospot (ELISpot) and by delayed-type hypersensitivity (DTH) testing.

WT1 expression of the hematologic malignancy was confirmed by either having greater than 15% of malignant cells react with anti-WT1 by immunohistochemistry or by having a positive quantitative reverse transcription polymerase chain reaction (RT-PCR) of WT1 compared with a negative control.

WT1 expression of the hematologic malignancy was confirmed by either having greater than 15% of malignant cells react with anti-WT1 by immunohistochemistry or by having a positive quantitative reverse transcription polymerase chain reaction (RT-PCR) of WT1 compared with a negative control. DTH skin testing was performed using KLH and with a cocktail of WT1 peptides as 2 separate injections. Enzyme-Linked Immunospot (ELISpot) was performed against each peptide and was considered positive if results were at least 10 spots above background on at least 2 measurements. DTH was considered positive if there was at least .5cm induration 48 to 72 hours after placement.

KLH is a neoantigen known to induce helper response was used concurrently as a vaccine adjuvant and control antigen. DTH skin testing was performed using KLH and with a cocktail of WT1 peptides as 2 separate injections. Enzyme-Linked Immunospot (ELISpot) was performed against each peptide and was considered positive if results were at least 10 spots above background on at least 2 measurements. DTH was considered positive if there was at least .5cm induration 48 to 72 hours after placement.

Progressive disease is at least a 20% increase in the sum of the longest diameter of all target lesions (i.e. tumor response). Response criteria for acute leukemia's is worse marrow classification (i.e., M status) with at least a 50% increase in the percentage of marrow blasts, or no change in marrow classification (i.e., M status), but a 50% or greater increase in absolute peripheral blast count or extent of medullary disease

National Cancer Institute (NCI)

Principal Investigator

Only recipients were monitored for adverse events.

Recipients

Donor lymphocyte collection via apheresis.

Donors

Age, Continuous

Ethnicity (NIH/OMB)

United States

Region of Enrollment

Hodgkin

ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia.

Disease

MA x 2

NMA, nonmyeloablative; MA, myeloablative; MAx2, myeloablative conditioning. This is standard terminology in the transplant field and refers to pre-transplant chemotherapy/radiation doses that require stem cell rescue.

Transplantation Type

MRD*

MSD, matched sibling donor; MRD\*, matched related donor. MRD\* was a 10/10 matched related parent for both transplantations. the first used marrow and the second used peripheral blood stem cells.; MUD, matched unrelated donor.

Fludarabine/cyclophosphamide

Cyclophosphamide, TBI, thiotepa

HSCT1:cyclo,TBI;HSCT2:busulfan, melphalan, etop

Cyclophosphamide, TBI

TBI, total body irradiation; cyclo, cyclophosphamide; etop, etoposide; HSCT, hematopoietic stem cell transplant

Conditioning Regimen

Cyclosporine

Sirolimus/tacrolimus, methotrexate

None after second BMT

Immunosuppression

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

Time Off Immunosuppression before Protocol Enrollment

6%-8% blasts

Multiple 1-2cm lymph nodes

5%-10% blasts

2% blasts

5% blasts

Pre-Enrollment Disease Status

Time to HCT to Relapse, mo

Time to First Vaccine (from day 0 of HCT), mo

Dr. Terry Fry

Toxicity

Data for the frequency and severity of GVHD was captured as an endpoint for this trial. The donor arm is not included here because they were not evaluated for this outcome measure; recipients only.

Number of Participants With Graft Versus Host Disease (GVHD) Greater Than or Equal to Grade 3

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Post Transplant Donor Lymphocyte Infusion	NCT00167180	Leukemia, Myelo... Lymphomas Multiple Myelom... Myelodysplastic... Leukemia, Lymph... Leukemia, Lymph... AML	Donor Lymphocyt... Induction Chemo...	1 Year - 70 Years	Masonic Cancer Center, University of Minnesota
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood	NCT00923910	Leukemia, Acute... Leukemia, Acute... Leukemia, Chron... Myelodysplastic... Non-Hodgkin's L...	WT1 Peptide-Pul... Donor Lymphocyt... IL-4 KLH WT1 Peptides Endotoxin Diphenhydramine Acetaminophen	1 Year - 74 Years	National Institutes of Health Clinical Center (CC)
Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT	NCT02472691	Leukemia, Myelo... Myelodysplastic... Leukemia, Myelo...	Lenalidomide Azacitidine Donor Lymphocyt...	18 Years - 99 Years	Heinrich-Heine University, Duesseldorf
Post Transplant Donor Lymphocyte Infusion	NCT00167180	Leukemia, Myelo... Lymphomas Multiple Myelom... Myelodysplastic... Leukemia, Lymph... Leukemia, Lymph... AML	Donor Lymphocyt... Induction Chemo...	1 Year - 70 Years	Masonic Cancer Center, University of Minnesota

Spots Global Cancer Trial Database for donor lymphocyte infusions